MicroRNA‑490‑3p suppresses the proliferation and invasion of hepatocellular carcinoma cells via targeting TMOD3

Wang,Honghua; Yang,Guobao; Yu,Yang; Gu,Peibing

doi:10.3892/ol.2020.11956

MicroRNA‑490‑3p suppresses the proliferation and invasion of hepatocellular carcinoma cells via targeting TMOD3

Authors:
- Honghua Wang
- Guobao Yang
- Yang Yu
- Peibing Gu
View Affiliations

Affiliations: Department of General Surgery, Xiangshui County People's Hospital, Yancheng, Jiangsu 224600, P.R. China
Published online on: August 6, 2020 https://doi.org/10.3892/ol.2020.11956
Article Number: 95
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. It has been reported that microRNAs (miRs) play important roles in the progression and development of HCC. The expression of miR‑490‑3p has been shown to be downregulated in HCC tissues. Therefore, the present study aimed to investigate the effects of miR‑490‑3p on HCC cells and the underlying mechanism. Cell Counting Kit‑8, flow cytometry, and Transwell migration and invasion assays were performed to determine the viability, apoptosis, migration and invasion of HCC cells, respectively. Furthermore, a luciferase activity assay was used to verify the association between miR‑490‑3p and its predicted target tropomodulin 3 (TMOD3). In addition, the protein levels of Bax, Bcl‑2, cleaved caspase‑3, TMOD3, phosphorylated (p)‑p38 and p‑ERK in HCC cells were detected using western blot analysis. The results demonstrated that the overexpression of miR‑490‑3p via transfection with miR‑490‑3p mimics significantly inhibited the proliferation of Huh‑7 and HEP 3B2.1‑7 cells. In addition, overexpression of miR‑490‑3p markedly suppressed the migration and invasion abilities of Huh‑7 cells. miR‑490‑3p mimics significantly induced liver cancer cell apoptosis via upregulating Bax and cleaved caspase‑3 and downregulating anti‑apoptotic protein Bcl‑2. Additionally, a luciferase activity assay indicated that TMOD3 is a downstream target gene of miR‑490‑3p. The protein levels of TMOD3, p‑p38 and p‑ERK were significantly downregulated in Huh‑7 cells following transfection with miR‑490‑3p mimics, and the overexpression of TMOD3 attenuated these effects. In conclusion, the aforementioned results suggest that the overexpression of miR‑490‑3p inhibited the proliferation and invasion of HCC cells by targeting TMOD3. Therefore, the miR‑490‑3p/TMOD3 axis may be a potent target for the treatment of HCC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Wallace MC, Preen D, Jeffrey GP and Adams LA: The evolving epidemiology of hepatocellular carcinoma: A global perspective. Expert Rev Gastroenterol Hepatol. 9:765–779. 2015. View Article : Google Scholar : PubMed/NCBI
3	Blanc JF, Frulio N, Chiche L, Bioulac-Sage P and Balabaud C: Hepatocellular adenoma management: Advances but still a long way to go. Hepat Oncol. 2:171–180. 2015. View Article : Google Scholar : PubMed/NCBI
4	Omyła-Staszewska J and Deptała A: Effective therapeutic management of hepatocellular carcinoma-on the basis of a clinical case. Contemp Oncol (Pozn). 16:60–63. 2012.PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
7	Li L, Yuan L, Luo J, Gao J, Guo J and Xie X: miR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 13:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
8	Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhu Z, Zhang X, Wang G and Zheng H: Role of microRNAs in hepatocellular carcinoma. Hepat Mon. 14:e186722014. View Article : Google Scholar : PubMed/NCBI
10	Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, et al: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
11	le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, et al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26:3699–3708. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zheng J, Sadot E, Vigidal JA, Klimstra DS, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR and Ventura A: Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS One. 13:e02007762018. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Gougelet A, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B, et al: Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut. 65:1024–1034. 2016. View Article : Google Scholar : PubMed/NCBI
15	Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and Dejean A: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 107:264–269. 2010. View Article : Google Scholar : PubMed/NCBI
16	Tian J, Xu YY, Li L and Hao Q: miR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res. 9:1127–1138. 2017.PubMed/NCBI
17	Kang NN, Ge SL, Zhang RQ, Huang YL, Liu SD and Wu KM: miR-490-3p inhibited the proliferation and metastasis of esophageal squamous cell carcinoma by targeting HMGA2. Eur Rev Med Pharmacol Sci. 22:8298–8305. 2018.PubMed/NCBI
18	Qu M, Li L and Zheng WC: Reduced miR-490-3p expression is associated with poor prognosis of Helicobacter pylori induced gastric cancer. Eur Rev Med Pharmacol Sci. 21:3384–3388. 2017.PubMed/NCBI
19	Liu X, He B, Xu T, Pan Y, Hu X, Chen X and Wang S: miR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer. J Cancer. 9:1218–1230. 2018. View Article : Google Scholar : PubMed/NCBI
20	Yamashiro S, Gokhin DS, Kimura S, Nowak RB and Fowler VM: Tropomodulins: Pointed-end capping proteins that regulate actin filament architecture in diverse cell types. Cytoskeleton (Hoboken). 69:337–370. 2012. View Article : Google Scholar : PubMed/NCBI
21	Fischer RS, Fritz-Six KL and Fowler VM: Pointed-end capping by tropomodulin3 negatively regulates endothelial cell motility. J Cell Biol. 161:371–380. 2003. View Article : Google Scholar : PubMed/NCBI
22	Jo YJ, Jang WI, Kim NH and Namgoong S: Tropomodulin-3 is essential in asymmetric division during mouse oocyte maturation. Sci Rep. 6:292042016. View Article : Google Scholar : PubMed/NCBI
23	Jin C, Chen Z, Shi W and Lian Q: Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway. Oncol Rep. 41:3060–3068. 2019.PubMed/NCBI
24	Zheng H, Yang Y, Hong YG, Wang MC, Yuan SX, Wang ZG, Bi FR, Hao LQ, Yan HL and Zhou WP: Tropomodulin 3 modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma metastasis. Mol Carcinog. 58:1897–1907. 2019. View Article : Google Scholar : PubMed/NCBI
25	Zhan XH, Jiao JW, Zhang HF, Xu XE, He JZ, Li RL, Zou HY, Wu ZY, Wang SH, Wu JY, et al: LOXL2 upregulates phosphorylation of ezrin to promote cytoskeletal reorganization and tumor cell invasion. Cancer Res. 79:4951–4964. 2019. View Article : Google Scholar : PubMed/NCBI
26	Paul D, Chanukuppa V, Reddy PJ, Taunk K, Adhav R, Srivastava S, Santra MK and Rapole S: Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma. J Proteomics. 138:95–105. 2016. View Article : Google Scholar : PubMed/NCBI